.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Deloitte
Boehringer Ingelheim
AstraZeneca
Merck
Johnson and Johnson
Farmers Insurance
Daiichi Sankyo
McKinsey
Mallinckrodt

Generated: September 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 5,968,914 protect, and when does it expire?


Patent ► Subscribe protects VISTOGARD and is included in one NDA.

This patent has one hundred and seventy-two patent family members in twenty-one countries.

Summary for Patent: ► Subscribe

Title: Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
Abstract:The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.
Inventor(s): von Borstel; Reid (Potomac, MD), Bamat; Michael K. (Potomac, MD)
Assignee: Pro-Neuron, Inc. (Rockville, MD)
Application Number:08/472,210
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,743,782 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
6,274,563 Acylated uridine and cytidine and uses thereof► Subscribe
5,246,708 Methods for promoting wound healing with deoxyribonucleosides► Subscribe
7,307,166Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis► Subscribe
7,166,581Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides► Subscribe
7,776,838Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides► Subscribe
6,020,322 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
6,054,441 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis► Subscribe
6,020,320 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
7,169,765Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria142221► Subscribe
Austria179615► Subscribe
Austria205850► Subscribe
Austria243039► Subscribe
Austria282627► Subscribe
Austria320813► Subscribe
Austria93236► Subscribe
Austria97574► Subscribe
Australia1417792► Subscribe
Australia2254492► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Healthtrust
Mallinckrodt
Citi
Harvard Business School
Medtronic
Chinese Patent Office
Cerilliant
QuintilesIMS
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot